
Are you an Associate Scientist within the ADME-Tox field looking for a role in industry wanting to contribute to global drug discovery? If so, then this could be the opportunity for you!
As an integral member of the Cyprotex team, you will be laboratory-based, working closely with our highly skilled and enthusiastic team to ensure that studies are performed to a high standard and within scheduled time frames. In addition, you will support the training and development of staff, improving the team’s knowledge and processes.
Role: Scientist (Tox)
Role Type: Permanent
Hours: Full time, 37.5 hours per week
Location: Alderley Park, Macclesfield, SK10 4TG.
Cyprotex vision is to be pioneers of innovative ADME-Tox partnerships, driving delivery of safer and more effective medicines. With state-of-the-art facilities and technical expertise, we specialise in in vitro and in silico ADME-Tox services, providing a wide range of assays tailored to our client’s needs. This includes in vitro screening to support discovery projects, regulatory studies to support preclinical and clinical development, specialist mechanistic in vitro human and animal toxicity models and PBPK/QSAR modelling expertise. As well as supporting clients directly, we have a strong focus on R&D.
Our Alderley Park site is set in the heart of Cheshire surrounded by stunning 400-acre estate, open green spaces, sweeping viewpoints, all within easy reach of Merseyside and Greater Manchester, Staffordshire, and Shropshire. Easy access to public transport.
Education, Qualifications and Experience
***Closing date for applications will be Friday 25th September 2026***
FR : Dans le cadre de sa politique Diversité, Evotec étudie, à compétences égales, toutes les candidatures dont celles des personnes en situation de handicap.
ENG : In the frame of our Diversity policy, Evotec considers, with equal competences, all applications including people with disabilities.

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients.
Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing.
We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI.
We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.